Shire opens up

Shire adopts open access policy for publication of Shire-supported research
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Cambridge, MA—Shire plc notes that they’ve implemented a new publication policy requiring the submission of all Shire-supported research manuscripts to journals which offer public availability via open access. This will allow the public to obtain free, unrestricted online access to Shire's research, promptly following publication. Shire's new open access policy, which went into effect on January 2 of this year, was announced today at the 2018 European Meeting of International Society for Medical Publication Professionals (ISMPP) taking place in London, UK, January 23-24.
Continue reading below...
A black mosquito is shown on pink human skin against a blurred green backdrop.
InfographicsDiscovering deeper insights into malaria research
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Read More
“Shire's new open access policy builds on our commitment to transparency and reflects our dedication to helping patients by allowing everyone to freely access and learn from our research findings,” said Christopher Rains, Head, Global Medical Affairs - Medical Shared Services at Shire. “We believe it's imperative to pioneer a new standard of access to publications that can encourage collaboration and drive medical innovation, with a goal of helping to bring innovative treatments to patients more rapidly. This may be particularly important when it comes to advancing new therapies for treating rare diseases.”
Shire reportedly believes that sharing clinical trial data with patients, healthcare providers, researchers and the public has the potential to improve public confidence in medicine and help all stakeholders make better healthcare decisions. Shire is thought to be the only company to report the results from all of its clinical studies posted on ClinicalTrials.gov.
“I believe Shire is the first biotechnology company to mandate that its research be published under an open access model. This approach helps to ensure that research findings can be can be built on by the widest possible audience in a manner that maximizes health and public benefit,” said Robert Kiley, Head of Open Research at the Wellcome Trust, a charitable foundation that supports scientific research.
Continue reading below...
A white, pink, and blue 3D molecular structure of a simple sugar is shown against a light purple background.
WebinarsAdding a little sugar: what glycomics can bring to medicine
Discover how glycoscience is transforming how scientists understand diseases and opening new doors for drug discovery.
Read More
In a presentation and panel discussion at the 2018 European Meeting of ISMPP entitled “Time to embrace change in medical publishing,” Kiley and Rains discussed the importance of increasing the accessibility of publications through open access. Although pharmaceutical companies fund around 60 percent of all medical research, the industry as a whole has been slow to adopt open access policies. With its commitment to an open access policy, Shire hopes to help usher in a new age of collaboration in global medical research.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up of a researcher using a stylus to draw or interact with digital molecular structures on a blue scientific interface.
When molecules outgrow the limits of sketches and strings, researchers need a new way to describe and communicate them.
Portrait of Scott Weitze, Vice President of Research and Technical Standards at My Green Lab, beside text that reads “Tell us what you know: Bringing sustainability into scientific research,” with the My Green Lab logo.
Laboratories account for a surprising share of global emissions and plastic waste, making sustainability a priority for modern research.
3D illustration of RNA molecules on a gradient blue background.
With diverse emerging modalities and innovative delivery strategies, RNA therapeutics are tackling complex diseases and unmet medical needs.
Drug Discovery News September 2025 Issue
Latest IssueVolume 21 • Issue 3 • September 2025

September 2025

September 2025 Issue

Explore this issue